Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

被引：0
作者：
Michele Kohli
Donna Lawrence
Jennifer Haig
Andrea Anonychuk
Nadia Demarteau
机构：
[1] OptumInsight,
[2] Health Economics and Outcomes Research,undefined
[3] GlaxoSmithKline Biologicals,undefined
[4] Global Vaccines Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Human papillomavirus; Cervical cancer; Vaccine; Cost-effectiveness; Markov model; Canada;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 276 条
  • [61] Bauch C(undefined)undefined undefined undefined undefined-undefined
  • [62] Merid MF(undefined)undefined undefined undefined undefined-undefined
  • [63] Van Kriekinge G(undefined)undefined undefined undefined undefined-undefined
  • [64] Demarteau N(undefined)undefined undefined undefined undefined-undefined
  • [65] Rogoza RM(undefined)undefined undefined undefined undefined-undefined
  • [66] Ferko N(undefined)undefined undefined undefined undefined-undefined
  • [67] Bentley J(undefined)undefined undefined undefined undefined-undefined
  • [68] Meijer CJLM(undefined)undefined undefined undefined undefined-undefined
  • [69] Berkhof J(undefined)undefined undefined undefined undefined-undefined
  • [70] Wang KL(undefined)undefined undefined undefined undefined-undefined
234567891011